2871-84-3

Basic information

• Product Name: (R)-3,4-bis(benzyloxy)-5-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)furan-2(5H)-one
• Synonyms: (R)-3,4-bis(benzyloxy)-5-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)furan-2(5H)-one
• CAS NO: 2871-84-3
• Molecular Weight: 396.44
• Mol File: 2871-84-3.mol
• Article Data: 20

Chemical Properties

• CAS DataBase Reference: (R)-3,4-bis(benzyloxy)-5-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)furan-2(5H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-3,4-bis(benzyloxy)-5-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)furan-2(5H)-one(2871-84-3)
• EPA Substance Registry System: (R)-3,4-bis(benzyloxy)-5-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)furan-2(5H)-one(2871-84-3)

Safety Data

• Hazardous Substances Data: 2871-84-3(Hazardous Substances Data)

Upstream product

• 100-39-0 benzyl bromide 
• 15042-01-0 5,6-O-isopropylidene-L-ascorbic acid 
• 100-44-7 benzyl chloride 
• 50-81-7 ascorbic acid 
• 15042-01-0 5,6-isopropylidene L-ascorbate 

Downstream Products

• 136767-82-3 3,4-dibenzyloxy-5-(2-hydroxyethylidene)-2(5H)-furanone 
• 185683-68-5 (S)-3,4-Bis-benzyloxy-5-((S)-2,2-dimethyl-[1,3]dioxolan-4-yl)-5H-furan-2-one 
• 86404-07-1 O³-benzyl-O⁵,O⁶-(1-methylethylidene)-L-ascorbic acid 
• 185675-41-6 3,4-bis(benzyloxy)-5-(2-hydroxyethyl)furan-2(5H)-one 
• 185675-57-4 (Z)-3,4-bis(benzyloxy)-5-(2-hydroxyethylidene)furan-2(5H)-one 
• 185675-42-7 Oxalic acid benzyl ester (R)-benzyloxycarbonyl-((S)-2,2-dimethyl-[1,3]dioxolan-4-yl)-methyl ester 
• 914771-19-0 [(2S)-2-[(2R)-3,4-dibenzyloxy-5-oxo-2H-furan-2-yl]-2-hydroxyethyl] hexadecanoate 

Relevant articles and documents

ANTITUMORAL ASCORBIC ACID ESTERS

The present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof or mixture of stereoisomers, wherein n is an integer from 0 to 10; R1 is a biradical selected from the group consisting of CH2, O, NH and SH; and R2 is a (C3-C15)alkyl radical. The present invention also provides pharmaceutical compositions comprising the compound of formula (I), and said compound and pharmaceutical compositions for use as a medicament, more particularly, for use in the treatment or prevention of a neoplastic disease, such as pancreatic cancer.

Design, synthesis, and neuroprotective effects of dual-brain targeting naproxen prodrug

A new dual-targeting naproxen prodrug conjugated with glucose and ascorbic acid for central nervous system (CNS) drug delivery was designed and synthesized in order to effectively deliver naproxen to the brain. Naproxen could be released from the prepared prodrugs when incubated with various buffers, mouse plasma, and brain homogenate. Also, the prodrug showed superior neuroprotective effect in vivo over naproxen. Our results suggest that chemical modification of therapeutics with warheads of glucose and ascorbic acid represents a promising and efficient strategy for the development of brain targeting prodrugs by utilizing the endogenous transportation mechanism of the warheads.

Continuous flow-ultrasonic synergy in click reactions for the synthesis of novel 1,2,3-triazolyl appended 4,5-unsaturated l-ascorbic acid derivatives

A combination of flow chemistry and batch-based synthetic procedures has been successfully applied to the assembly of novel 4,5-unsaturated l-ascorbic acid series 6a-6n with diverse C-6-substituted 1,2,3-triazole moiety. We report herein the first Cu(i)-catalyzed 1,3-dipolar cycloaddition of azido functionalized l-ascorbic acid derivative and selected alkynes to provide target 1,2,3-triazolyl appended 4,5-didehydro-5,6-dideoxy-l-ascorbic acid library 6a-6n under both micro-flow and batch conditions. Implementation of ultrasound with flow chemistry accelerated hour-scale reaction conditions in batch to the minute range in micro-flow device and considerably improved the yields for the flow syntheses of 6a-6n. Moreover, the synergistic use of microreactor technology and ultrasonic irradiation highlights the sustainable eco-friendly aspect of utilized method.